Are pharmacological considerations of relevance in hormone replacement therapy for prevention of chronic disease?

Journal of Obstetrics and Gynaecology

Volumn 23, Issue 3, 2003, Pages 263-266

  Lippert, T H ^a,b   Seeger, H ^a   Mueck, A O ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYEQUILENIN; 4 HYDROXYESTRONE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DRUG METABOLITE; ESTRADIOL; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NANDROLONE; PROGESTERONE; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; CARDIOVASCULAR SYMPTOM; CHRONIC DISEASE; COLORECTAL CARCINOMA; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SYNTHESIS; ESTROGEN DEFICIENCY; FIRST PASS EFFECT; GENOTOXICITY; HORMONE SUBSTITUTION; HUMAN; INSULIN RESISTANCE; LOW DRUG DOSE; MENOPAUSAL SYNDROME; OSTEOPOROSIS; PRIORITY JOURNAL; PROGESTERONE METABOLISM; REVIEW;

CARDIOVASCULAR DISEASES; CHEMISTRY, PHARMACEUTICAL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; RANDOMIZED CONTROLLED TRIALS;

EID: 0037701782     PISSN: 01443615     EISSN: None     Source Type: Journal    
DOI: 10.1080/01443610310000100060     Document Type: Review

References (26)

1. Adams M.R., Register T.C., Golden D.L., Wagner J.D. and Williams J.K. (1997) Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arteriosclerosis, Thrombosis and Vascular Biology, 17, 217-221.
2. Chen Y., Liu X., Pisha E., Constantinou A.I., Hua Y., Shen L., van Breemen R.B., Elguindi E.C., Blond S.Y., Zhang F. and Bolton J.L. (2000) A metabolite of equine estrogens, 4-hydroxyequilenin induces DNA damage and apoptosis in breast cancer cell lines. Chemical Research in Toxicology, 13, 342-350.
3. Cline J.M., Soderqvist G., von Schoultz E., Skoog L. and von Schoultz B. (1996) Effects of hormone replacement therapy on mammary gland of surgically postmenopausal cynomolgus macaques. American Journal of Obstetrics and Gynecology, 174, 93-100.
4. Cline J.M., Soderqvist G., von Schoultz E., Skoog L. and von Schoultz B. (1998) Effects of conjugated estrogens, medroxy-progesterone and tamoxifen on the mammary glands of macaques. Breast Cancer Research and Treatment, 48, 221-229.
5. Colditz G.A. and Rosner B. (2000) Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. American Journal of Epidemiology, 152, 950-964.
6. Dey M. (1999) The new science of hormone replacement therapy. Journal of the Birtish Menopause Society, Supplement S2, 4-5.
7. Enserink M. (2002) Women's health. The vanishing promises of hormone replacement. Science, 297, 325-326.
8. Fletcher S.W. and Colditz G.A. (2002) Failure of estrogen plus progestin therapy for prevention. Journal of the American Medical Association, 288, 366-368.
9. Godsland I.F. (1998) Effects on carbohydrate metabolism. In: Estrogens and Progestogens in Clinical Practice, edited by Fraser I.S., Jansen R.P.S., Lobo R.A. and Whitehead M.I., pp. 773-785. London: Churchill Livingstone.
10. Grady D., Herrington D., Bittner V., Blumenthal R., Davidson M., Hlatky M., Hsia J., Hulley S., Herd A., Khan S., Newby L.K., Waters D., Vittinghoff E. and Wenger N. (2002) Cardiovascular disease outcomes during 6.8 years of hormone replacement therapy. Journal of the American Medical Association, 288, 49-57.
11. Haarbo J., Leth-Espensen P., Stender S. and Christiansen C. (1991) Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. Journal of Clinical Investigation, 87, 1274-1279.
12. Hofseth L.J., Raafat A.M., Osuch J.R., Pathak D.R., Slomski C.A. and Haslam S.Z. (1999) Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. Journal of Clinical Endocrinology and Metabolism, 84, 4559-4565.
13. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B. and Vittinghoff E. (1998) Randomized trial for estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Journal of the American Medical Association, 280, 605-613.
14. Klein R. (1998) The composition of premarin. International Journal of Fertility, 43, 223.
15. Lane G., Siddle N., Ryder T.A., Pryse-Davies J., King R.J.B. and Whitehead M.I. (1986) Is Provera the ideal progestogen for addition to postmenopausal estrogen therapy? Fertility and Sterility, 45, 345-352.
16. Lippert T.H., Seeger H. and Mueck A.O. (2000a) The impact of endogenous estradiol metabolites on carcinogenesis. Steroids, 65, 357-369.
17. Lippert T.H., Mueck A.O. and Seeger H. (2000b) Is the use of conjugated equine estrogens in hormone replacement therapy still appropriate? British Journal of Clinical Pharmacology, 49, 489-490.
18. Lippert T.H., Seeger H. and Mueck A.O. (2001) Pharmacology and toxicology of different estrogens. Gynecological Endocrinology, 15 (Suppl. 4), 26-33.
19. Liu X., Yao J., Pisha E., Yang Y., Hua Y., van Breemen R.B. and Bolton J.L. (2002) Oxidative DNA damage induced by equine estrogen metabolites: role of estrogen receptor alpha. Chemical Research in Toxicology, 15, 512-519.
20. Lobo R.A., Kelsey J. and Marcus R. (2000) Menopause, Biology and Pathobiology. San Diego, Academic Press.
21. MacLennan A.H., MacLennan A., Wenzel S., Chambers H.M. and Eckert K. (1993) Continuous low-dose oestrogen and progestogen hormone replacement therapy: a randomised trial. Medical Journal of Australia, 159, 102-106.
22. Parfitt K. (1999) Martindale, The complete Drug Reference, 32nd edition, pp. 1457-1458. London, Pharmaceutuical press.
23. Ross R.K., Paganini-Hill A., Wan P.C. and Pike M.C. (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. Journal of the National Cancer Institute, 92, 328-332.
24. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L. and Hoover R. (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. Journal of the American Medical Association, 283, 485-491.
25. Williams J.K., Honore E.K., Washburn S.A. and Clarkson T.B. (1994) Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. Journal of the American College of Cardiology, 24, 1757-1761.
26. Writing Group for the Women's Health Initiative Invetigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. Journal of the American Medical Association, 288, 312-333.